https://www.selleckchem.com/products/sop1812.html
8% reduction for APEX-Aβ42 and 48.6% for Simoa-Aβ42/Aβ4 compared to the situation where only PET imaging is used. Moreover, with 100% sensitivity, APEX-Aβ42 pre-screening does not increase the required number of initial participants. With its high diagnostic performance, APEX is an ideal candidate for Aβ+ subject identification, monitoring and primary care screening, and could efficiently enrich clinical trials with Aβ+ participants whilst halving recruitment costs. With its high diagnostic performance, APEX is an ideal candidate for
Like
Comment
Share
